Leela Barham and Tim Wilsdon discuss the potential impact that value-based pricing (VBP) may have in the UK and the broader implications for developing international models of Health Technology Assessment (HTA). The article can be found here:
Keytruda LoE: A seismic shift for oncology?
Immune checkpoint inhibitors (ICIs) have changed the face of oncology treatment since their initial entry in the early 2010s. Driven mostly by the group of...